Empirically defining treatment response and remission in body dysmorphic disorder

Abstract Background The number of clinical trials in body dysmorphic disorder (BDD) has steadily increased in recent years. As the number of studies grows, it is important to define the most empirically useful definitions for response and remission in order to enhance field-wide consistency and comparisons of treatment outcomes across studies. In this study, we aim to operationally define treatment response and remission in BDD. Method We pooled data from three randomized controlled trials of cognitive-behavior therapy (CBT) for BDD (combined n = 153) conducted at four academic sites in Sweden, the USA, and England. Using signal detection methods, we examined the Yale-Brown Obsessive Compulsive Scale modified for BDD (BDD–YBOCS) score that most reliably identified patients who responded to CBT and those who achieved remission from BDD symptoms at the end of treatment. Results A BDD–YBOCS reduction ⩾30% was most predictive of treatment response as defined by the Clinical Global Impression (CGI) – Improvement scale (sensitivity 0.89, specificity 0.91, 91% correctly classified). At post-treatment, a BDD–YBOCS score ⩽16 was the best predictor of full or partial symptom remission (sensitivity 0.85, specificity 0.99, 97% correctly classified), defined by the CGI – Severity scale. Conclusion Based on these results, we propose conceptual and operational definitions of response and full or partial remission in BDD. A consensus regarding these constructs will improve the interpretation and comparison of future clinical trials, as well as improve communication among researchers, clinicians, and patients. Further research is needed, especially regarding definitions of full remission, recovery, and relapse.

[1]  J. Enander,et al.  Cognitive-behavioral therapy for body dysmorphic disorder: A systematic review and meta-analysis of randomized controlled trials. , 2016, Clinical psychology review.

[2]  W. Menard,et al.  Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial. , 2016, The American journal of psychiatry.

[3]  G. Andersson,et al.  Therapist guided internet based cognitive behavioural therapy for body dysmorphic disorder: single blind randomised controlled trial , 2016, British Medical Journal.

[4]  H. Simpson,et al.  Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive‐compulsive disorder , 2016, World psychiatry : official journal of the World Psychiatric Association.

[5]  G. Krebs,et al.  A Pilot Randomized Controlled Trial of Cognitive-Behavioral Therapy for Adolescents With Body Dysmorphic Disorder. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  D. Veale,et al.  Long-Term Outcome of Cognitive Behavior Therapy for Body Dysmorphic Disorder: A Naturalistic Case Series of 1 to 4 Years After a Controlled Trial. , 2015, Behavior therapy.

[7]  W. Menard,et al.  Psychometric evaluation of the Yale–Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) , 2014 .

[8]  K. Phillips,et al.  Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial. , 2014, Behavior therapy.

[9]  E. Foa,et al.  Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. , 2013, The Journal of clinical psychiatry.

[10]  W. Menard,et al.  A 4-year prospective observational follow-up study of course and predictors of course in body dysmorphic disorder , 2012, Psychological Medicine.

[11]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[12]  Bruno Falissard,et al.  The improved Clinical Global Impression Scale (iCGI): development and validation in depression , 2007, BMC psychiatry.

[13]  W. Menard,et al.  A 12-month follow-up study of the course of body dysmorphic disorder. , 2006, The American journal of psychiatry.

[14]  W. Menard,et al.  Suicidal ideation and suicide attempts in body dysmorphic disorder. , 2005, The Journal of clinical psychiatry.

[15]  M. Liebowitz,et al.  Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder , 2003, Psychological Medicine.

[16]  K. Phillips,et al.  A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. , 2002, Archives of general psychiatry.

[17]  E. Hollander,et al.  Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. , 1999, Archives of general psychiatry.

[18]  K. Gournay,et al.  Body Dysmorphic Disorder , 1996, British Journal of Psychiatry.

[19]  D J Kupfer,et al.  Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. , 1991, Archives of general psychiatry.

[20]  N. Andreasen,et al.  The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. , 1987, Archives of general psychiatry.

[21]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[22]  D. Veale,et al.  Body dysmorphic disorder and olfactory reference disorder: proposals for ICD-11. , 2014, Revista brasileira de psiquiatria.

[23]  E. Hollander,et al.  A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. , 1997, Psychopharmacology bulletin.